The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice

K-REx Repository

Show simple item record

dc.contributor.author Opoku-Acheampong, Alexander B.
dc.contributor.author Nelsen, Michelle K.
dc.contributor.author Unis, Dave
dc.contributor.author Lindshield, Brian L.
dc.date.accessioned 2012-02-02T19:30:45Z
dc.date.available 2012-02-02T19:30:45Z
dc.date.issued 2012-02-02
dc.identifier.uri http://hdl.handle.net/2097/13449
dc.description.abstract Background: 5 alpha-reductase 1 (5alphaR1) and 5alpha-reductase 2 (5alphaR2) convert testosterone into the more potent androgen dihydrotestosterone. 5alphaR2 is the main isoenzyme in normal prostate tissue; however, most prostate tumors have increased 5alphaR1 and decreased 5alphaR2 expression. Previously, finasteride (5alphaR2 inhibitor) treatment begun 3 weeks post-tumor implantation had no effect on Dunning R3327-H rat prostate tumor growth. We believe the tumor compensated for finasteride treatment by increasing tumor 5alphaR1 expression or activity. We hypothesize that finasteride treatment would not significantly alter tumor growth even if begun before tumor implantation, whereas dutasteride (5alphaR1 and 5alphaR2 inhibitor) treatment would decrease tumor growth regardless of whether treatment was initiated before or after tumor implantation. Methodology/Principal Findings: Sixty 8-week-old male nude mice were randomized to Control, Pre- and Post-Finasteride, and Pre- and Post-Dutasteride (83.3 mg drug/kg diet) diet groups. Pre- and post-groups began their treatment diets 1–2 weeks prior to or 3 weeks after subcutaneous injection of 1x10[5th power] WPE1-NA22 human prostate cancer cells, respectively. Tumors were allowed to grow for 22 weeks; tumor areas, body weights, and food intakes were measured weekly. At study’s conclusion, prostate and seminal vesicle weights were significantly decreased in all treatment groups versus the control; dutasteride intake significantly decreased seminal vesicle weights compared to finasteride intake. No differences were measured in final tumor areas or tumor weights between groups, likely due to poor tumor growth. In follow-up studies, proliferation of WPE1-NA22 prostate cancer cells and parent line RWPE-1 prostate epithelial cells were unaltered by treatment with testosterone, dihydrotestosterone, or mibolerone, suggesting that these cell lines are not androgensensitive. Conclusion: The lack of response of WPE1-NA22 prostate cancer cells to androgen treatment may explain the inadequate tumor growth observed. Additional studies are needed to determine whether finasteride and dutasteride are effective in decreasing prostate cancer development/growth. en_US
dc.relation.uri www.plosone.org en_US
dc.subject Prostate cancer en_US
dc.subject Finasteride en_US
dc.subject Dutasteride en_US
dc.subject WPE-NA22 prostate cancer cells en_US
dc.title The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice en_US
dc.type Article (publisher version) en_US
dc.date.published 2012 en_US
dc.citation.doi doi:10.1371/journal.pone.0029068 en_US
dc.citation.issue 1 en_US
dc.citation.jtitle PLoS ONE en_US
dc.citation.spage e29068 en_US
dc.citation.volume 7 en_US
dc.contributor.authoreid blindsh en_US
dc.contributor.authoreid alexach en_US
dc.contributor.authoreid daveunis en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search K-REx


Advanced Search

Browse

My Account

Statistics








Center for the

Advancement of Digital

Scholarship

118 Hale Library

Manhattan KS 66506


(785) 532-7444

cads@k-state.edu